Aventis, Bayer end talks on biological venture

financial terms not reached

31.01.2003

PARIS (AFX) - Aventis SA said it has ended it talks with Bayer AG to form a biological products joint venture. In a statement, Aventis said no financial terms were reached. Under the proposed venture, the companies had planned to combine Aventis' Aventis Behring unit with Bayer Healthcare's biological products division. Aventis said it is loking at alternatives for the future of Aventis Behring.

Weitere News aus dem Ressort Wirtschaft & Finanzen

Meistgelesene News

Weitere News von unseren anderen Portalen

Vis-à-Vis mit UV/VIS